Rein Therapeutics

Mr. Musso served on Lung’s board since April 2022 and joined the company’s board in August 2023.

Dr. Windsor served as President and Chief Operating Officer of Aileron from October 2023 before becoming CEO.

Dr. Cory M. Hogaboam leads research at Cedars Sinai Medical Center’s Women’s Guild Lung Institute, using genomic and proteomic methods.

Reinhard Ambros has been on the company’s board of directors since June 2013, after retiring from Novartis Venture Funds.

Harnessing fibrosis, unleashing life

Harnessing fibrosis, unleashing life

Rein Therapeutics secures FDA Fast Track designation for its experimental drug **LTI-03**, targeting **idiopathic pulmonary fibrosis**. The biopharmaceutical company specializes in orphan pulmonary and fibrosis treatments, advancing a pipeline of first-in-class medicines. This designation accelerates the development and review process for LTI-03, potentially improving patient access to novel therapies.

Aug 2026Rein TherapeuticsNews article

Rein Therapeutics releases its second-quarter 2026 financial results, detailing revenue, expenses, and operational progress. The biotech company highlights advancements in its pipeline, including preclinical data for a lead asset targeting neurodegenerative diseases. Management also updates investors on strategic partnerships and cash runway projections.

Aug 2026GlobeNewswireNews article

Rein Therapeutics has priced a $50 million public offering at $1 per share. The biotech company focuses on developing novel therapies. This offering marks a key step in its financing strategy.

May 2026Investing.com CanadaNews article

Rein Therapeutics updates progress on its Phase 2 **RENEW** trial testing **LTI-03** as a treatment for **idiopathic pulmonary fibrosis (IPF)**. The company reports findings from the ongoing study, assessing safety and efficacy of the investigational therapy. LTI-03 targets fibrotic lung disease, a progressive and often fatal condition with limited treatment options.

Apr 2026Stock TitanNews article